China Isotope & Radiation Corp. (HK:1763) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
China Isotope & Radiation Corporation’s subsidiary, CNNC Chengying, has achieved a milestone by obtaining a registration certificate from China’s National Medical Products Administration for its innovative Gamma-ray Stereotactic Radiotherapy System. This advanced medical equipment, powered by domestically-produced cobalt-60, promises to enhance the efficiency and precision of cancer treatments in China. The company anticipates that this achievement will support China’s ‘Healthy China 2030’ initiative and bolster national health security.
For further insights into HK:1763 stock, check out TipRanks’ Stock Analysis page.